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MutationsObjective/background: The in vitro drug-susceptibility testing of Mycobacterium tuberculosis
reports isolates as resistant or susceptible on the basis of single critical concentrations.
It is evident that drug resistance in M. tuberculosis is quite heterogeneous, and involves
low level, moderate level, and high level of drug-resistant phenotypes. Thus, the aim of
our study was to correlate rrs (X52917) and eis (AF144099) promoter mutations, found in
M. tuberculosis isolates, with corresponding minimum inhibitory concentrations of amika-
cin, kanamycin, and capreomycin.
Methods: Ninety M. tuberculosis clinical isolates were analyzed in this study. The mini-
mum inhibitory concentrations were determined by MGIT 960 for 59 isolates with
resistance-associated mutations in the rrs and eis promoter gene regions, and 31 iso-
lates with wild-type sequences, as determined by the GenoType MTBDRsl (version 1)
assay.
Results: The rrs A1401G mutation was identified in 48 isolates resistant to the second-
line injectables. The eis promoter mutations C-14T (n = 3), G-10C (n = 3), G-10A (n = 3),
and C-12T (n = 2) were found within 11 isolates with various resistance profiles to the
second-line injectables. Thirty-one isolates had wild-type sequences for the rrs and eis
promoter gene regions of interest, one of which was amikacin, kanamycin, and capre-
omycin resistant. The isolates with the rrs A1401G mutation had amikacin, kanamycin,
and capreomycin minimum inhibitory concentrations of >40 mg/L, >20 mg/L, and 5–
15 mg/L, respectively. The isolates with eis promoter mutations had amikacin, kanamy-
cin, and capreomycin minimum inhibitory concentrations of 0.25–1.0 mg/L, 0.625–10 mg/
L, and 0.625–2.5 mg/L, respectively.
2 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 1 –6Conclusion: This study provides a preliminary basis for the prediction of phenotypic-
resistance levels to the second-line injectables based upon the presence of genetic muta-
tions associated with amikacin, kanamycin, and capreomycin resistance. The results sug-
gest that isolates with eis promoter mutations have consistently lower resistance levels to
amikacin, kanamycin, and capreomycin than isolates with the rrs A1401G mutation.
 2015 Production and hosting by Elsevier Ltd. on behalf of Asian African Society for
Mycobacteriology.Introduction
Drug-resistant tuberculosis (TB) poses a major threat to TB
control efforts worldwide. There is an increasing global inci-
dence of multidrug-resistant TB (MDR-TB) and extremely
drug-resistant TB (XDR-TB), characterized by resistance to
isoniazid, rifampin, a fluoroquinolone, and at least one of
three second-line injectable (SLI) drugs: amikacin (AMK),
kanamycin (KAN), and/or capreomycin (CAP). The effective
treatment of MDR-TB, as well as the prevention of XDR-TB,
is reliant upon the appropriate use of these SLIs. In order to
establish appropriate treatment regimens, and to prevent
the amplification of SLI resistance, it is critical that MDR-TB
patients have full drug-susceptibility profiles established for
their particular Mycobacterium tuberculosis infections prior to
treatment [1].
The conventional diagnosis of drug-resistant M. tuberculosis
relies upon the slow growth of mycobacterium cultures, and
can take anywhere from several weeks to months to generate
results [2]. While methods for the conventional diagnosis of
MDR-TB are well established and generally effective, the
culture-based detection of SLI resistance is more complicated
and results are less reliable [3]. As such, rapid molecular
diagnostic tests, detecting genetic mutations associated with
drug resistance, are essential to the future diagnosis and
management of M/XDR-TB.
A high level of cross-resistance has been observed
between the aminoglycosides AMK and KAN [4,5]. CAP, a cyc-
lic polypeptide, can be used as a substitute, although it is
structurally dissimilar to the aminoglycosides [4,6]. For
patients with MDR-TB, if CAP resistance additionally occurs,
an increased incidence of treatment failure and patient mor-
tality is observed [7]. Furthermore, studies conducted in clin-
ical isolates and laboratory-generated M. tuberculosis mutants
have noted the additional occurrence of cross-resistance
between AMK/KAN and CAP, limiting the treatment options
for these infections [4,5,8]. SLI resistance is mainly conveyed
by mutations in the rrs and eis promoter gene regions of
M. tuberculosis isolates. AMK/KAN and CAP are known to
effect protein synthesis in M. tuberculosis, and resistance to
these compounds is primarily conveyed by changes in the
16S ribosomal RNA (encoded by the rrs gene) [4,5,9]. A high-
level AMK/KAN resistance and a lower-level CAP resistance
can be caused by mutation in rrs A1401G [4]. The transfer of
an acetyl group from acetyl coenzyme A to an amine group
of aminoglycoside is catalyzed by eis (aminoglycoside acetyl-
transferase); a multiacetylation capability at the 20-, 3-, or 60
positions of aminoglycoside antibiotics is shown by the eis
of M. tuberculosis [10]. Although these resistance mechanismshave been well defined, it is critical to additionally correlate
specific genetic mutations with levels of SLI resistance in
order to guide M/XDR-TB treatment regimens and improve
patient outcomes. Herein, we establish the minimum
inhibitory concentrations (MICs) for 90 clinical M. tuberculosis
isolates with specific rrs and eis promoter mutations.
Materials and methods
Setting and ethical approval
Awritten consent waswaived for all participants, as the study
was carried out on 90 archived isolates for which pyrose-
quencing (PSQ), GenoType MTBDRsl assay (version 1) and
MGIT 960 drug-susceptibility testing (DST) (utilizing theWorld
Health Organization-approved critical concentrations), was
performed previously. Sample collection, MGIT culture, Geno-
Type MTBDRsl assay, and PSQ were performed at the
Mycobacteriology Laboratory of the P. D. Hinduja Hospital &
Medical Research Centre, a tertiary-care hospital in Mumbai,
India with a referral bias toward TB treatment nonresponders.
This study was approved by the Institutional Review Board of
P. D. Hinduja Hospital & Medical Research Centre.
Phenotypic MGIT DST
We performed a standardized DST to KAN using the BACTEC
MGIT 960 System (Becton, Dickinson and Company Diagnostic
Systems, Sparks, MD, USA) with the EpiCenter software. The
manufacturer’s protocol was strictly followed for preparation
of the inocula, inoculation, and incubation. For KAN, a break-
point concentration of 2.5 mg/Lwas utilized based upon previ-
ous findings [11]. The critical concentrations of AMK and CAP
were 1.0 mg/L and 2.5 mg/L, respectively. The stock solutions
of AMK, KAN, and CAP (Sigma–Aldrich, St. Louis, Missouri,
USA) were prepared by dissolving the compounds in distilled
water. The drugs were filtered, further diluted with distilled
water, and stored at80 C for up to 6 months. A genotypically
confirmed resistant strain anda pan-susceptible strain, H37Rv,
were tested weekly by the MGIT 960 DSTas a quality control.
Quantitative DST
Six concentrations of KAN and seven concentrations of AMK
and CAP were used to establish the MICs for theM. tuberculosis
isolates included in this study. Two concentrations below the
critical concentration (0.25 mg/L and 0.5 mg/L) and three
concentrations above the critical concentration (4.0 mg/L,
20.0 mg/L, and 40.0 mg/L) were used to establish the AMK
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(0.625 mg/L and 1.25 mg/L) and three concentrations above
the critical concentration (5.0 mg/L, 10.0 mg/L, and 20.0 mg/
L) were used for KAN; and two concentrations below the crit-
ical concentration (0.625 mg/L and 1.25 mg/L) and four con-
centrations above the critical concentration (5.0 mg/L,
10.0 mg/L, 15.0 mg/L, and 30.0 mg/L) were used for CAP.
GenoType MTBDRsl assay
The procedure for the GenoType MTBDRsl assay was as
follows:
1. DNA extraction: DNA was extracted from all decontami-
nated patient samples using a GenoLyse kit (Hain Life-
science, Nehren, Germany).
2. Polymerase chain reaction (PCR): Multiplex PCR amplifica-
tion was conducted for the rrs gene of interest utilizing
biotinylated primers. PCR was performed with the follow-
ing cycling conditions: initial denaturation 95 C/15 min;
(denaturation 95 C/30 s, annealing 58 C/2 min [10 cycles]);
(denaturation 95 C/25 s, annealing 53 C/40 s, extension
70 C/40 s [30 cycles]); and final extension 70 C/8 min.
3. Hybridization: Reverse hybridization/GenoType MTBDRsl
assay was performed as per manufacturer’s instructions
(Hain Lifescience) [12].
4. Analysis: The GenoType MTBDRsl assay evaluates the rrs
gene for mutations at positions 1401/1402 and 1484. The
absence of the test wild-type (WT) marker, WT1, and the
presence of the mutation (MUT) probe, MUT1, correspond
to the A1401Gmutation, while the absence of the test WT2
marker and the presence of the probe MUT2 correspond to
the G1484T mutation.PSQ
A total of 20 M. tuberculosis isolates were additionally rrs
sequence confirmed and evaluated for the presence of the
eis promoter mutations by PSQ. Reagents from the HotStarTaq
kit and deoxynucleotide-triphosphate mixtures (Qiagen,
Valencia, CA, USA) were used in the PCR master mix. PSQ
was performed as follows:
1. DNA extraction: The PSQ assay utilized crude DNA,
extracted by a simple heating procedure (95 C, 25 min).
2. PCR solutions: Each PCR reaction contained 2.5 lL of
extracted isolate DNA and 22.5 lL of the PCR master mix
(1 PCR buffer, 2.5 mM MgCl2, 0.96 mM deoxynucleotide-
triphosphate mixture, 1 Q-Solution, 0.5 lM rrs or eis pro-
moter primers, and 1 U of HotStarTaq).
3. PCR steps: The initial activation was done with HotstarTaq
polymerase at 95 C for 15 min, followed by 50 cycles of
amplification (94 C for 15 s, 60 C for 30 s, and 72 C for
20 s), and a final extension at 72 C for 5 min.
4. PSQ reaction: PSQ was conducted for the 6 to 47 regions
of the eis promoter, and the 1401/1402 region of the rrs
gene. PSQ was performedwith PyroMark Q96 reagents, uti-
lizing the sequence-analysis mode of the PyroMark Q96 ID
system (Qiagen) [13].Results
Phenotypic DST and MIC results
Sixty phenotypically XDR-TB strains were included in this
study. Eleven (found to have eis promoter mutations) were
resistant to KAN at the critical concentration, but sensitive
to AMK and CAP. Forty-eight isolates (determined to have
the rrs A1401G mutation) were found to be resistant to KAN,
AMK, and CAP. One isolate (with WT sequences for both the
rrs and eis promoter) was also resistant to KAN, AMK, and
CAP at the critical concentration. Thirty isolates were pan
susceptible to all drugs tested. The MICs of AMK, KAN, and
CAP for all isolates are shown in Table 1.
Genotypic results
The agreement between the GenoType MTBDRsl assay results
(based solely upon the presence of resistance-associated rrs
mutations) and the phenotypic DST was 97% for AMK, 96%
for KAN, and 86% for CAP. The sequencing and DST results
for the 20 isolates subjected to PSQ are summarized in Table 2.
One isolate, found to be phenotypically resistant to the three
SLIs, had rrs and eis promoter WT sequences by both the Gen-
oType MTBDRsl and PSQ assays.
Correlation of KAN MICs with resistance-associated
mutations
The isolates harboring the rrs A1401G mutation had AMK,
KAN, and CAP MICs of >40 mg/L, >20 mg/L, and 5–15 mg/L,
respectively, whereas the isolates with eis promoter muta-
tions were found to have AMK, KAN, and CAP MICs ranging
from 0.25 mg/L to 1.0 mg/L, 5.0 mg/L to 10 mg/L, and
0.625 mg/L to 2.5 mg/L, respectively (Table 1). As such, the
rrs A1401G mutation correlated with high-level AMK and
KAN resistance, and moderate-level CAP resistance. The eis
promoter mutations correlated with low-level AMK and CAP
resistance, and moderate-level KAN resistance.
Discussion
This study correlates specific rrs and eis promoter mutations
identified in M. tuberculosis clinical isolates with AMK, KAN,
and CAP phenotypic-resistance levels. Overall, the MIC ranges
forM. tuberculosis isolates with WT rrs and eis gene sequences
were different from the MIC ranges for the isolates harboring
resistance-associated mutations in these gene regions. The
rrs and eis promoter mutations associated with SLI resistance
were found in 59 of the 90 M. tuberculosis isolates evaluated in
this study. These two genes, alone, appeared to be highly sen-
sitive markers for SLI resistance, as only one of the 60 SLI-
resistant isolates evaluated in the study was determined to
have WT sequences for the gene regions evaluated. This iso-
late may have had SLI resistance-associated mutations in
other genes, such as tlyA and gidB, that were not assessed
in this study. Overall, our results provide a preliminary basis
for the prediction of SLI phenotypic-resistance levels based
upon the presence or absence of specific resistance-
Table 1 – Mutations found within Mycobacterium tuberculosis clinical isolates and their associated minimum inhibitory
concentrations against the second-line injectables.
Mutation LPAa Total no.
of isolates
No. of isolates MIC (mg/L)
AMK KAN CAP
rrs
A1401G MUT1 48 25 >40 >20 5.0
20 >40 >20 10
3 >40 >20 15
eis
G-10C WT 3 1 0.5 2.5 0.625
1 0.25 5.0 0.625
1 0.5 5.0 0.625
G-10A WT 3 1 1.0 5.0 2.5
1 1.0 2.5 0.125
1 0.5 10 0.625
C-12T WT 2 1 0.5 5.0 0.625
1 0.25 5.0 0.625
C-14T WT 3 1 0.25 10 0.625
1 1.0 10 1.25
1 0.25 0.625 0.625
WT
WTb 1 1 4.0 10 5.0
WT 30 25 0.25 0.625 0.625
5 0.5 0.625 1.25
Note: AMK = amikacin; CAP = capreomycin; KAN = kanamycin; WT = wild type.
a Line probe assay.
b One isolate, characterized as WT, but resistant to AMK, KAN, and CAP at their respective break points, could contain a mutation in gene
regions not assessed by MTBDRsl or pyrosequencing.
Table 2 – Pyrosequencing results for 20 Mycobacterium tuberculosis clinical isolates with wild-type MTBDRsl assay results.
No. of isolates GenoType MTBDRsl assay DST (critical concentration) PSQ
AMK KAN CAP
8 WT Susceptible Resistant Susceptible eis mutation
3 WT Susceptible Susceptible Susceptible eis mutation
4 WT Susceptible Susceptible Susceptible WT
1 WT Resistant Resistant Resistant WT
4 rrs MUT1 Resistant Resistant Resistant A1401G
Note. AMK = amikacin; CAP = capreomycin; DST = drug-susceptibility testing; KAN = kanamycin; PSQ = pyrosequencing; WT = wild type.
4 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 1 –6associated mutations in both the rrs and eis promoter gene
regions of M. tuberculosis clinical isolates.
The peak serum concentrations for KAN, AMK, and CAP
have been previously reported at 22.5 mg/L, 20–40 mg/L, and
10–30 mg/L, respectively [14,15]. Taking these concentrations
into account, M. tuberculosis resistance levels to each drug
may be categorized as low, moderate, or high. As noted in
Table 1, the rrs A1401G mutation appears to consistently cor-
respond to a high level of AMK and KAN resistance (MICs
>40 mg/L, >20 mg/L). The KAN MICs for isolates with the
A1401G mutation have been previously documented to be as
high as >80 mg/L, and clinical studies have confirmed that
this particular rrs mutation confers KAN resistance even at
these high concentrations, with additional cross-resistance
to AMK with MICs of >64 mg/L [5] and, to a lesser extent,
CAP with MICs of 5–10 mg/L [16]. Conversely, isolates with
eis promoter mutations have been documented to be resis-
tant to KAN, but susceptible to AMK and CAP at their respec-tive break points [4,16–18]. Our study identified 11 isolates
with eis promoter mutations. These isolates had low- to
moderate-level KAN resistance, and a low level of resistance
to AMK and CAP. These eis promoter mutations, C-14T, G-
10C, G-10A, and C-12T, have been shown to result in a signif-
icant increase in eis transcript levels, as well as in a corre-
sponding increase in the expression of an enzyme that
acetylates KAN, inactivating the drug [18,19].
Importantly, although the Eis enzyme was found to have
some cross-reactivity with AMK, the activity was limited,
and eis mutants are found to be largely susceptible to this
other aminoglycoside, as reflected by current testing and
treatment guidelines [17,18]. As Eis utilizes KAN as a substrate
up to three times more efficiently than AMK, the noted lack of
cross-resistance is unsurprising. This preferential substrate
utilization by Eis is likely a result of aminoglycoside structural
differences; AMK sterically delays acetylation, as it contains
an L-hydroxyaminobuteroyl amide group substitution in the
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that, even though rrs mutations confer cross-resistance to
KAN and AMK, KAN-resistant isolates with eis promoter
mutations may still be sensitive to AMK, and thus, both
KAN and AMK should be considered individually when deter-
mining phenotypic drug-susceptibility profiles [17]. Indeed,
the eis promoter mutations were found only within AMK-
and CAP-susceptible isolates in our study, suggesting that
these drugs could potentially be used to treat strains housing
eis promoter mutations.
Our observation that different eis promoter mutations cor-
respond to varying levels of phenotypic resistance to KAN,
AMK, and CAP is also notable. The eis promoter mutations
C-14T and G-10A corresponded to low- or moderate-level
resistance to KAN, with KAN MICs generally ranging from
2.5 lg/mL to 10 lg/mL, and MICs corresponding with
low-level resistance to AMK and CAP (0.25–1.0 mg/L and
0.625–2.5 mg/L), comparable with values reported by previous
studies [16,18]. The association of the C-12T mutation with
KAN resistance, however, has been a point of contention. In
one study, C-12T mutants were shown to have slightly
increased KAN MICs, although they retained sensitivity to
KAN and AMK [18]. Another study found isolates with the
C-12T mutation to have KAN resistance at an MIC of 5.0 mg/
L, although the CAP MICs were <2.5 mg/L [16]. Overall, all
studies found aminoglycoside MICs to be lower for eis
promoter mutants compared to rrs mutants [10,16,18]. This
supports our characterization of eis promoter mutants as
‘‘low- to moderate-level” KAN resistant with MICs ranging
from 0.625 mg/L to 10 mg/L, ‘‘low-level” AMK resistant
with MICs from 0.25 mg/L to 1.0 mg/L, and ‘‘low-level”
CAP resistant with MICs from 0.625 mg/L to 2.5 mg/L.
However, the overlap seen for KAN MIC ranges for the various
mutants (i.e., MICs for -14T mutants were not very different
than -10A or -12T mutants) suggests the need for further
studies to clearly define associated phenotypic-resistance
levels.
The sequencing of additional gene regions not evaluated
in this study, such as gidB and tlyA, might additionally con-
tribute to our understanding of the genetic basis of the
observed SLI phenotypic-resistance levels of M. tuberculosis
clinical isolates. These initial results, however, confirm that
specific mutations in the rrs and eis promoter are promising
markers for improved diagnostic assay sensitivity and speci-
ficity for the detection of injectable-drug resistance. Further-
more, our findings suggest that each drug should be
considered independently when considering the results of
molecular diagnostic assays, in order to determine the most
effective treatment regimens for M/XDR-TB cases.Conclusion
These results suggest that the various mutations associated
with SLI resistance may be correlated with specific SLI
phenotypic-resistance levels. The rrs canonical mutation,
A1401G, was found to confer a high level of AMK and KAN
resistance to M. tuberculosis isolates, but a moderate level of
CAP resistance. The eis promoter mutations were generally
determined to confer lower levels of AMK and CAP resistance,and low to moderate levels of KAN resistance. Thus, together,
the rrs and eis promoter mutations appear to have utility as
molecular markers for aminoglycoside-resistance levels,
directing optimal treatment regimens for M/XDR-TB cases.
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